Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MCRB
MCRB logo

MCRB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Seres Therapeutics Inc (MCRB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.610
1 Day change
2.32%
52 Week Range
29.980
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Seres Therapeutics Inc (MCRB) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral to bearish, there are no significant positive catalysts, and the options data does not suggest strong bullish sentiment. With no recent news or financial data to support a growth narrative, it is best to hold off on investing in this stock right now.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 56.824, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 6.45, with resistance at 7.402. Overall, the technical indicators suggest a neutral to bearish trend.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low Put-Call ratios indicate a lack of significant bearish sentiment, but the overall volume and open interest data do not suggest strong bullish activity either.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
2

Positive Catalysts

  • NULL identified. There is no recent news or event-driven catalyst to support a bullish case for the stock.

Neutral/Negative Catalysts

  • Bearish moving averages and lack of strong trading trends from hedge funds or insiders. Additionally, the stock has a 60% chance of declining by -2.86% in the next day, according to candlestick pattern analysis.

Financial Performance

No financial data available for the latest quarter, making it difficult to assess the company's growth trends or financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available for evaluation.

Wall Street analysts forecast MCRB stock price to rise
2 Analyst Rating
Wall Street analysts forecast MCRB stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.460
sliders
Low
22
Averages
22
High
22
Current: 6.460
sliders
Low
22
Averages
22
High
22
Canaccord
Buy
maintain
$14 -> $22
AI Analysis
2025-09-24
Reason
Canaccord
Price Target
$14 -> $22
AI Analysis
2025-09-24
maintain
Buy
Reason
Canaccord raised the firm's price target on Seres Therapeutics to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres' proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions while also noting Seres is reducing staff by 25%, including August 2025 reductions, which should provide sufficient cash to fund operations into 2Q26.

People Also Watch